Investigation of Miconazole as an Inhibitor of Endothelium-Derived Hyperpolarizing Factor
Miconazole, L-NMMA, Bradykinin
Maladies Cardiovasculaires
+ Maladies vasculaires
+ Anévrisme
Étude thérapeutique
Résumé
Date de début de l'étude : 1 février 2000
Date à laquelle le premier participant a commencé l'étude.The vascular endothelium synthesizes at least three potent vasodilator substances: nitric oxide (NO), prostacyclin and an endothelium-derived hyperpolarizing factor (EDHF). EDHF release is stimulated by receptor-dependent agonists such as acetylcholine and bradykinin (BK), and leads to hyperpolarization of the underlying smooth muscle cells presumably by opening Ca(2+)-activated K(+) channels. Indirect pharmacologic evidence suggests that EDHF is a cytochrome P450-derived arachidonic acid metabolite, presumably an epoxide. Numerous inhibitors of EDHF have been defined in animal tissues. Of these, miconazole has proven to be safe when administered to humans as a topical and parenteral antifungal agent. At levels that are attained with routine clinical use, it has a rapid onset of action with high specificity of inhibition of EDHF in animal models. This study is designed to investigate the safety and efficacy of intra-arterial miconazole in inhibiting BK-mediated forearm vasodilation in normal volunteers.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.15 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.Volontaires sains autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Healthy male or female volunteers (age 21-60 years). No presence of intercurrent illness. No current smoking (within previous 5 years). No hypertension (greater than 140/90). No diabetes. No hypercholesterolemia (total cholesterol greater than 240 mg/dl). No pregnancy or menopause. No renal failure (creatinine greater than 1.4 mg/dl). No allergies to miconazole, parabens, castor oil or aspirin. No bleeding disorders. No consumption of any medications during the last one week, including vitamins and unconventional medications.
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, United StatesOuvrir National Heart, Lung and Blood Institute (NHLBI) dans Google Maps